July 6, 2007
Prezista and Etravirine Meds Win Big in Studies
Results from several ongoing studies show that two HIV meds, etravirine (TMC-125), as well as Prezista (darunavir) boosted with Norvir (ritonavir) , can outperform such other drugs as Kaletra (lopinavir/ritonavir) in treatment-experienced patients. The findings, in a special HIV edition of the medical journal The Lancet, mark a huge p.r. boon for the pharmaceutical company Tibotec, which makes etravirine and Prezista.
[Go to top]